Clinical and histopathological predictors of outcome in malignant meningioma
We investigated possible clinical and histopathological prognostic factors in a malignant meningioma cohort with comprehensive long-term population-based follow-up data. Twenty-four consecutive patients treated surgically for malignant meningioma at the Department of Neurosurgery and the Department of Pathology, Rigshospitalet, Copenhagen, Denmark, from December 2000 to March 2014 were retrospectively evaluated regarding progression-free survival (PFS) and overall survival (OS). Clinical parameters were recorded. All specimens underwent immunohistochemical analysis for Ki-67 and phosphohistone-H3 (PHH3). Prognostication was assessed with Cox proportional hazard regression analysis. The median follow-up was 46.1 months (range 0.7–150.7). The median progression-free survival was 16.5 months (95% CI 11.4–43.0) and the median overall survival was 46.6 months (95% CI 20.4–NA). Six patients were alive at the end of follow-up; two of these had not experienced a recurrence. No clinical parameter showed significant association with PFS or OS. Mitotic index (MI) was significantly associated with PFS and OS, and PHH3 MI with PFS. Immunohistochemical reactivity of Ki-67 > 10% was a negative predictor of PFS (HR 3.92, 95% CI 1.47–10.4, p = 0.0063) and OS (HR 3.35, 95% CI 1.12–10.1, p = 0.0313). The histological subgrouping of grade III meningioma into anaplastic and non-anaplastic revealed increased PFS for the latter (HR 4.57, CI 95% 1.32–15.7, p = 0.0164). We could not verify previous clinical parameters as prognostic factors in malignant meningioma. MI and the PHH3 MI were prognostic within WHO grade III meningiomas for PFS. An overall tumor staining of Ki-67 > 10% correlated with PFS and OS within grade III tumors.
KeywordsMalignant meningioma Prognostic factors Ki-67 Phosphohistone-H3
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This study was approved by the Danish Ethical Committee (approval number H-6-2014-010).
The ethical approval granted waiver of informed consent, as the project does not inflict any additional potential health risks to these patients, besides those which they already have been exposed to and are familiar with, in relation to the diagnostic and the therapeutic treatment. Patients who beforehand had denied the use of their leftover diagnostic material in research were not included, but there were no such requests among the cases of interest.
- 2.Adeberg S, Hartmann C, Welzel T, Rieken S, Habermehl D, von Deimling A, Combs SE (2012) Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas d clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. 83. https://doi.org/10.1016/j.ijrobp.2011.08.010
- 3.Balasubramanian SK, Sharma M, Silva D, Karivedu V, Schmitt P, Stevens GH, Barnett GH, Prayson RA, Elson P, Suh JH, Murphy ES, Chao ST (2017) Longitudinal experience with WHO grade III (anaplastic) meningiomas at a single institution. J Neuro-Oncol 131:555–563. https://doi.org/10.1007/s11060-016-2321-8 CrossRefGoogle Scholar
- 10.Duregon E, Cassenti A, Pittaro A, Ventura L, Senetta R, Rudà R, Cassoni P (2015) Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds. Neuro-Oncology 17:663–669. https://doi.org/10.1093/neuonc/nov002 CrossRefGoogle Scholar
- 11.Ehresman JS, Garzon-Muvdi T, Rogers D, Lim M, Gallia GL, Weingart J, Brem H, Bettegowda C, Chaichana KL (2018) The relevance of Simpson grade resections in modern neurosurgical treatment of World Health Organization grade I, II, and III meningiomas. World Neurosurg 109:e588–e593. https://doi.org/10.1016/j.wneu.2017.10.028 CrossRefGoogle Scholar
- 13.Fukushima S, Terasaki M, Sakata K, Miyagi N, Kato S, Sugita Y, Shigemori M (2009) Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases. Brain Tumor Pathol 26:51–57. https://doi.org/10.1007/s10014-009-0249-9 CrossRefGoogle Scholar
- 15.Hua L, Zhu H, Li J, Tang H, Kuang D (2017) Prognostic value of estrogen receptor in WHO grade III meningioma: a long-term follow-up study from a single institution. 1–9. https://doi.org/10.3171/2017.2.JNS162566
- 17.Iwasaki T, Matsushita M, Nonaka D, Kato M, Nagata K, Murakami I, Hayashi K (2015) Phosphohistone-H3 (PHH3) is prognostic relevant in Merkel cell carcinomas but Merkel cell polyomavirus is a more powerful prognostic factor than AJCC clinical stage, PHH3, Ki-67 or mitotic indices. Pathol Int 65:404–409. https://doi.org/10.1111/pin.12305 CrossRefGoogle Scholar
- 18.Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, Rogers L, Schiff D, Vogelbaum M, Weber D, Wen P (2014) Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro-Oncology 16:829–840. https://doi.org/10.1093/neuonc/not330 CrossRefGoogle Scholar
- 19.Katz LM, Hielscher T, Liechty B, Silverman J, Zagzag D, Sen R, Wu P, Golfinos JG, Reuss D, Neidert MC, Wirsching H-G, Baumgarten P, Herold-Mende C, Wick W, Harter PN, Weller M, von Deimling A, Snuderl M, Sen C, Sahm F (2018) Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathol 135:955–963. https://doi.org/10.1007/s00401-018-1844-9 CrossRefGoogle Scholar
- 24.Louis, DN (2016) WHO classification of tumours of the central nervous system. International Agency for Research on Cancer, FranceGoogle Scholar
- 25.Louis D, Ohgaki H, Wiestler O, Cavenee W (2016) WHO classification of tumours of the central nervous system, 4th edn. International Agency for Research on Cancer, World Health Organization, LyonGoogle Scholar
- 28.Ozturk Sari S, Taskin OC, Gundogdu G, Yegen G, Onder S, Keskin M, Saglam S, Ozluk Y, Gulluoglu M, Mete O (2016) The impact of phosphohistone-H3-assisted mitotic count and Ki67 score in the determination of tumor grade and prediction of distant metastasis in well-differentiated pancreatic neuroendocrine tumors. Endocr Pathol 27:162–170. https://doi.org/10.1007/s12022-016-9424-9 CrossRefGoogle Scholar
- 29.Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM (1998) The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer 82:2262–2269. https://doi.org/10.1002/(SICI)1097-0142(19980601)82:11<2262::AID-CNCR23>3.0.CO;2-R CrossRefGoogle Scholar
- 30.Peyre M, Gauchotte G, Giry M, Froehlich S, Pallud J, Graillon T, Bielle F, Cazals-Hatem D, Varlet P, Figarella-Branger D, Loiseau H, Kalamarides M (2017) De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors. Neuro-Oncology 20:1–9. https://doi.org/10.1093/neuonc/nox231 Google Scholar
- 32.Ribalta T, McCutcheon IE, Aldape KD, Bruner JM, Fuller GN (2004) The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol 28:1532–1536. https://doi.org/10.1097/01.pas.0000141389.06925.d5 CrossRefGoogle Scholar
- 34.Rosenberg LA, Prayson RA, Lee J, Reddy C, Chao ST, Barnett GH, Vogelbaum MA, Suh JH (2009) Long-term experience with World Health Organization grade III (malignant) meningiomas at a single institution. Int J Radiat Oncol Biol Phys 74:427–432. https://doi.org/10.1016/j.ijrobp.2008.08.018 CrossRefGoogle Scholar
- 35.Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, Okonechnikov K, Koelsche C, Reuss DE, Capper D, Sturm D, Wirsching HG, Berghoff AS, Baumgarten P, Kratz A, Huang K, Wefers AK, Hovestadt V, Sill M, Ellis HP, Kurian KM, Okuducu AF, Jungk C, Drueschler K, Schick M, Bewerunge-Hudler M, Mawrin C, Seiz-Rosenhagen M, Ketter R, Simon M, Westphal M, Lamszus K, Becker A, Koch A, Schittenhelm J, Rushing EJ, Collins VP, Brehmer S, Chavez L, Platten M, Hänggi D, Unterberg A, Paulus W, Wick W, Pfister SM, Mittelbronn M, Preusser M, Herold-Mende C, Weller M, von Deimling A (2017) DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 18:682–694. https://doi.org/10.1016/S1470-2045(17)30155-9 CrossRefGoogle Scholar